相比其他在研的第四代EGFR-TKI,BLU-945是目前进度最快的四代EGFR-TKI之一,其克服耐药的临床前数据显示出高效的抗肿瘤活性。我们也期待BLU-945能尽快公布更多的积极临床数据,下一步就是早日获批上市,为奥希替尼耐药的患者带来救赎。扫描下方二维码,或者直接电话咨询医瘤界医学部(400-880-3716),为癌友患者们分享更多信息。免责声明:医瘤界为肿瘤科普平台,文本参考来源于网络,版权归原作者所有。该文章仅供分享,如涉嫌侵犯您的著作权请联系我们删除,谢谢!参考资料1.Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy | BioSpace2.FDA Clears IND for ACE2016 in EGFR-Expressing Solid Tumors (targetedonc.com)3.A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer (NSCLC): SYMPHONY trial in progress. | Journal of Clinical Oncology (ascopubs.org)4.Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC) | Cancer Research | American Association for Cancer Research (aacrjournals.org)